HSK 47977
Alternative Names: HSK-47977Latest Information Update: 23 Dec 2025
At a glance
- Originator Haisco Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto oncogene proteins c-bcl-6 degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
- Preclinical Diffuse large B cell lymphoma
Most Recent Events
- 28 Aug 2025 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (PO) (NCT07283796)
- 25 Apr 2025 Preclinical trials in Diffuse large B cell lymphoma in China (PO), prior to April 2025
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Diffuse large B cell lymphoma presented at the 116th Annual Meeting of the American Association for Cancer Research 2025 (AACR-2025)